ImmunityBio Receives FDA Review for Anktiva Label Expansion
ImmunityBio (IBRX) saw a premarket rise of approximately 9% after the U.S. Food and Drug Administration accepted its application to expand the label for its bladder cancer therapy, Anktiva.
Tickers: $IBRX
Topics: biotech bladder cancer immunotherapy